Scientists are discovering why many Alzheimer's medicines are failing and identify one that might work.

According to a new study, a "vicious feedback loop" at the heart of Alzheimer's disease could explain why so many drug trials in hopes of treating this disease fail.

The same research has shown that a clinically approved drug that appears to break this cycle has the power to protect against memory loss in mice, thus offering hope for future treatment.

By using nerve cells grown in a dish, the researchers discovered that beta-amyloid – which causes brain degeneration in Alzheimer's disease – stimulates its own production when it destroys a brain connection.

This means that the drugs created to try to clean the beta-amyloid could actually lead a lost battle.

"We show that there is a positive and vicious feedback loop in which beta-amyloid directs its own production," said Dr. Richard Killick of King's College London, who led the research.

"We think that once this feedback loop gets out of control, it's too late for the beta amyloid targeting drugs to be effective, which could explain why so many drug trials against the disease have occurred." Alzheimer's have failed. "

The overproduction of beta-amyloid destroys brain connections, or synapses, and has been a natural target for scientists seeking a cure for this devastating disease.

The researchers also found that a protein called Dkk1 has a central role in the beta-amyloid feedback loop, and may even stimulate its production.

In their research, published in the journal Translational Psychiatry, they suggest that targeting Dkk1 – as an anti-stroke medication called fasudil does – could be a way to overcome Alzheimer’s. In mice, they showed that fasudil is capable of preserving both synapses and memory.

Though researchers cautiously welcomed the findings, Dr Diego Gomez-Nicola, a neuroscientist at the University of Southampton, said further experimental work would be needed before anti-amyloid approaches could be written off completely.

Dr Carol Routledge, director of research at Alzheimer’s Research UK, agreed there was still a lot that remained unknown.

“While this study provides solid evidence about an important molecular mechanism driving damage in Alzheimer’s, it is based on research in cells and mice,” she said.

“Fasudil is an approved drug for other health conditions, but is currently used in a critical care setting and would need to go through robust safety tests in trials of people with Alzheimer’s disease.”

Nevertheless, Dr James Pickett, head of research at the Alzheimer’s Society, said such repurposing of existing drugs “could be a real treasure trove”.

“There haven’t been any new drugs last 15 years, so it’s very promising to have uncovered a reason why some of that research may have failed and a potential solution, which builds on our own previous research into this area,” he said.

“Although only tested on mice in this instance, it is encouraging to see a drug already used in humans, fasudil, has the potential to reduce the build-up of amyloid. At this stage we don’t know if the effect will be the same in humans, so further exploration is needed.”

The findings emerged as another study showed that purging “zombie” cells – which have stopped functioning but haven’t died – from the brain could open up new methods of treating dementia.

That research, published in the journal Nature, was welcomed as “exciting” by Alzheimer’s specialists, although once again they noted that the science was a long way from yielding any results in humans.

“We need to exercise caution as to not over-interpret its relevance to dementia in humans as the study was performed in a mouse model,” said Professor Lawrence Rajendran of Kings College London, who was not involved in the study.

“Nevertheless, this study shows promise for alternative ways to tackle the disease which has been so far difficult using traditional approaches.”